Online citations, reference lists, and bibliographies.

Chitosan-based Nanoparticles For Improving Immunization Against Hepatitis B Infection.

C. Prego, P. Paolicelli, B. Díaz, Sara Vicente, A. Sánchez, Á. González-Fernández, M. Alonso
Published 2010 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The design of effective vaccine delivery vehicles is opening up new possibilities for making immunization more equitable, safe and efficient. In this work, we purpose polysaccharidic-based nanoparticles as delivery structures for virus-like particle antigens, using recombinant hepatitis B surface antigen (rHBsAg) as a model. Polysaccharidic-based nanoparticles were prepared using a very mild ionic gelation technique, by cross-linking the polysaccharide chitosan (CS) with a counter ion. The resulting nanoparticles could be easily isolated with a size in the nanometric range (160-200 nm) and positive surface charge (+6 to +10 mV). More importantly, CS-based nanoparticles allowed the efficient association of the antigen (>60%) while maintaining the antigenic epitope intact, as determined by ELISA and Western blot. The entrapped antigen was further released in vitro from the nanoparticles in a sustained manner without compromising its antigenicity. In addition, loaded CS-based nanoparticles were stable, and protected the associated antigen during storage, either as an aqueous suspension under different temperature conditions (+4 degrees C and -20 degrees C), or as a dried form after freeze-drying the nanoparticles. Finally, immunization studies showed the induction of important seroprotection rates after intramuscular administration of the nanoparticles, indicating their adjuvant capacity. In fact, CS-based nanoparticles were able to induce anti-HBsAg IgG levels up to 5500 mIU/ml, values 9-fold the conventional alum-adsorbed vaccine. In conclusion, we report here a polysaccharidic nanocarrier which exhibits a number of in vitro and in vivo features that make it a promising adjuvant for vaccine delivery of subunit antigens.
This paper references
10.1038/nri1439
NALT- versus PEYER'S-patch-mediated mucosal immunity
H. Kiyono (2004)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.1166/JNN.2006.435
Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery.
M. Cuña (2006)
10.1023/B:PHAM.0000019307.27058.a1
Spray-Coating for Biopharmaceutical Powder Formulations: Beyond the Conventional Scale and Its Application
Y. Maa (2004)
10.1126/SCIENCE.311.5758.162
The New World of Global Health
J. Cohen (2006)
10.1016/S0169-409X(00)00123-X
Polysaccharide colloidal particles as delivery systems for macromolecules.
K. Janes (2001)
10.1016/j.ymeth.2006.07.018
Virus-like particles: Passport to immune recognition
E. Grgacic (2006)
10.3109/10837459709022619
Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses.
M. Katakam (1997)
10.1016/J.JCONREL.2006.01.012
Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
L. Feng (2006)
10.1023/A:1018908705446
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
R. Fernández-Urrusuno (2004)
10.1002/jps.2600730103
Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels.
M. I. Zapata (1984)
10.1023/A:1018942118148
Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres
M. Alonso (1993)
10.1016/S0264-410X(01)00423-6
ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
M. Westerink (2001)
10.1126/SCIENCE.305.5681.147
The Global Vaccination Gap
A. Mahmoud (2004)
10.1038/nri1777
Mucosal vaccines: the promise and the challenge
M. Neutra (2006)
10.1002/JPS.10042
Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
L. Shi (2002)
10.1016/J.VACCINE.2007.03.038
Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin.
M. L. Kang (2007)
10.1016/J.ADDR.2005.12.003
Needle-free vaccine delivery.
E. Giudice (2006)
Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration
R. Fernández-Urrusuno (1999)
10.1016/S0168-8278(03)00152-1
Hepatitis B vaccines.
D. Shouval (2003)
10.1016/J.VACCINE.2003.11.064
Pluronic F127-based systemic vaccine delivery systems.
C. Coeshott (2004)
10.1517/17425247.2.5.843
The potential of chitosan for the oral administration of peptides
C. Prego (2005)
10.1038/nrd1176
Recent advances in the discovery and delivery of vaccine adjuvants
D. O'hagan (2003)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1002/JPS.10294
Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
Y. Maa (2003)
10.1016/S0264-410X(99)00391-6
Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate.
S. Wang (2000)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins.
F. Gavilanes (1982)
10.1111/J.1523-1755.2005.00689.X
Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
Norella Kong Chiew Tong (2005)
10.1016/J.ADDR.2004.10.001
Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems.
M. Friede (2005)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)



This paper is referenced by
10.3389/fimmu.2018.02224
Nanoparticle Vaccines Against Infectious Diseases
R. Pati (2018)
Chitosan and its derivatives as the carrier for intranasal drug delivery
Jiaojiao Ding (2012)
10.1007/978-3-7091-1818-4_7
Sugar-Based Immune Adjuvants for Use in Recombinant, Viral Vector, DNA and Other Styles of Vaccines
N. Petrovsky (2014)
10.1016/B978-0-12-415769-9.00015-7
Chapter 15 – Nanotoxicology
Rosana Simón-Vázquez (2012)
10.3390/vaccines3030638
Small Wonders—The Use of Nanoparticles for Delivering Antigen
A. Taki (2015)
10.1016/j.jconrel.2012.03.017
Chitosan-based drug nanocarriers: where do we stand?
M. Garcia-Fuentes (2012)
10.1007/978-3-319-08084-0_8
Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation
Maria Luisa de la Fuente (2014)
10.1080/21691401.2019.1577888
HBs antigen and mannose loading on the surface of iron oxide nanoparticles in order to immuno-targeting: fabrication, characterization, cellular and humoral immunoassay
Mahsa Rezaei (2019)
10.1007/978-1-4939-1417-3_10
Polymeric Particulates for Subunit Vaccine Delivery
Thomas B. Schuster (2015)
10.1007/978-3-319-41926-8_3
Chitosan Based Nanomaterials and Its Applications
Saurabh Bhatia (2016)
10.33549/PHYSIOLRES.933422
Macromolecular systems for vaccine delivery.
G. Mužíková (2016)
10.1016/J.MOLLIQ.2017.06.071
Self-assembled scorpion venom proteins cross-linked chitosan nanoparticles for use in the immunotherapy
Karla Samara Rocha Soares (2017)
10.1016/j.ejpb.2015.09.019
Protamine-based nanoparticles as new antigen delivery systems.
J. V. González-Aramundiz (2015)
10.1016/j.ijbiomac.2020.03.124
Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization.
Surendra Saraf (2020)
10.1021/acsnano.8b07662
Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen
Tamara G. Dacoba (2019)
10.1007/978-981-13-0950-2_16
Biodegradable Polymeric Nanocarrier-Based Immunotherapy in Hepatitis Vaccination.
Seo Jin Hong (2018)
10.3390/toxins10040158
Antivenom Production against Bothrops jararaca and Bothrops erythromelas Snake Venoms Using Cross-Linked Chitosan Nanoparticles as an Immunoadjuvant
Karla Samara Rocha Soares (2018)
10.1007/s12393-015-9116-0
Edible Bio-Based Nanostructures: Delivery, Absorption and Potential Toxicity
J. Martins (2015)
10.3389/fimmu.2018.00791
Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System
Mercedes Peleteiro (2018)
10.1016/j.actbio.2020.03.020
Advancements in prophylactic and therapeutic nanovaccines
P. Bhardwaj (2020)
10.3390/vaccines3030730
Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines
Jorge F. Correia-Pinto (2015)
10.1016/j.ijpharm.2017.03.081
A novel serum-stable liver targeted cytotoxic system using valerate-conjugated chitosan nanoparticles surface decorated with glycyrrhizin.
Eman M. El-Marakby (2017)
A new approach to antigen delivery using nanoparticle templating system
A. Taki (2014)
10.1016/j.ijpharm.2012.04.047
Vaccine delivery carriers: insights and future perspectives.
J. Correia-Pinto (2013)
10.1016/J.JDDST.2015.08.010
Multi-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides
Jorge F. Correia-Pinto (2015)
10.1016/j.ijpharm.2012.04.040
Immunogenicity of protein aggregates--concerns and realities.
W. Wang (2012)
10.1016/j.addr.2015.10.004
Current advances in self-assembled nanogel delivery systems for immunotherapy.
Y. Tahara (2015)
10.1016/j.ijpharm.2014.01.037
Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions.
K. T. Mody (2014)
10.1142/9789814520652_0007
Polysaccharide-Based Nanocarriers for Drug Delivery
Carmen Teijeiro (2014)
10.1016/j.ejpb.2017.12.003
Single dose HBsAg CS‐&ggr;‐PGA nanogels induce potent protective immune responses against HBV infection
Haigang Wang (2018)
10.1007/s11095-014-1419-y
Biomaterials for Nanoparticle Vaccine Delivery Systems
P. Sahdev (2014)
10.1371/journal.pone.0202997
Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques
H. Li (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar